lexisnexis whitepaper

Download whitepaper – Pharmaceutical & Life sciences: Third Party Due Diligence

Whitepaper by LexisNexis Few industries are as exposed to risk as the pharmaceuticals and life sciences. It is no longer enough to carry out basic checks alone on third-parties. Companies must engage in enhanced due diligence if they are to avoid the large fines and regulatory penalties. Effective third-party due diligence is increasingly recognized as a strategic driver for sustainable …

Effective third party due diligence for pharma companies: understanding current trends and issues

At the 2014 Pharma Compliance Europe event, Michael Harris, Head of Enhanced Due Dilligance-EMEA, Thomson Reuters, gave the presentation “Effective third party due diligence for Pharma companies: understanding current trends and issues.” Download and learn: Who are we dealing with? Detailed accurate reliable intelligence Types of risks faced in the pharma and medical device industry in China Top countries for enhanced …